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Part 1
Introduction and meeting objectives
In all societies, the burden and cost of allergic and chronic 
respiratory diseases are increasing rapidly. Most economies 
are struggling to deliver modern health care effectively. 
There is a need to support the transformation of the health 
care system for integrated care with organizational health 
literacy. MASK (Mobile Airways Sentinel NetworK) (1), 
a new development of the ARIA (Allergic Rhinitis and its 
Impact on Asthma) initiative, and POLLAR (Impact of Air 
POLLution on Asthma and Rhinitis, EIT Health) (2), in 
collaboration with professional and patient organizations in 
the field of allergy and airway diseases, are proposing real-
life integrated care pathways (ICPs) (3)-centred around 
the patient with rhinitis and using mHealth monitoring of 
environmental exposure (4).
An expert meeting took place at the Pasteur Institute 
in Paris, December 3, 2018. The aim was to discuss next-
generation care pathways: (I) Patient participation, health 
literacy and self-care through technology-assisted “patient 
activation”; (II) Implementation of care pathways by 
pharmacists and (III) Next-generation guidelines assessing 
the recommendations of GRADE guidelines in rhinitis 
and asthma using real-world evidence (RWE) assessed by 
mobile technology.
The EU (5) and global political agendas are of great 
importance in supporting health care transformation. 
MASK has been recognized by DG Santé as a Good 
Practice (6) in the field of digitally-enabled, integrated, 
person-centred care.
The one-day meeting objectives were clear (Figure 1). 
The meeting was followed by a workshop. The present 
paper reports the background of the two-day meeting.
Organizations supporting the meeting
Impact of air POLLution on Asthma and Rhinitis 
(POLLAR)
The interactions between air pollution and pollen in 
the urban environment are potentially important for 
patients suffering from allergic rhinitis (AR). Urban 
traffic air pollutants can interact with pollen. They can 
trigger nasal symptoms and even impact sleep and work 
activity. POLLAR is a project of the European Institute of 
Innovation and Technology (EIT Health) (2). POLLAR is 
based on an application, the Allergy Diary (MASK-air®) (1), 
that will be combined with a new tool allowing queries 
on allergen, pollen, sleep quality and disorders as well as 
existing longitudinal and geolocalized pollution data (7).
The Reference Site Collaborative Network (RSCN) 
of the European Innovation Partnership on Active and 
Healthy Ageing (EIP on AHA)
Seventy-four Reference Sites of the EIP on AHA were 
recognized in 2016 by the European Commission for 
their commitment to excellence in investing and scaling 
up innovative solutions for active and healthy ageing. The 
RSCN brings together the EIP on AHA Reference Sites 
into a single forum. The goals are to promote cooperation, 
share and transfer good practice and solutions in the 
development and scaling up of health and care strategies, 
policies and service delivery models, while at the same time 
supporting the action groups in their work.
Global Alliance against Chronic Respiratory Diseases 
(GARD) demonstration project
GARD has approved some demonstration projects to 
strengthen its activities and implementation strategy. MASK 
is one of them (8).
Other organizations supporting the meeting
Twenty-one organizations and 3 patient’s organizations 
supported the meeting (Figure 2).
Planetary health
The environment quality for human health is an important 
paradigm of modern public health (9). During the last 
decades, our knowledge of the influence of the environment 
degradation on health has improved substantially. The last 
WHO assessment estimated that environmental factors 
caused the loss of 21% (596 million) DALYS in 2012 (1). 
However, this systematic assessment included neither 
climate change nor the related factors such as temperature 
increase.
Though there are growing concerns that the health 
impacts of climate change will be important, there are still 
very limited strategies in the public health knowledge and 
service systems (10). This relative silent attitude is in sharp 
contrast to the evidence of the fast degradation of natural 
and climate systems. We know that today we live in a new 
geological period, the Anthropocene, which is functionally 
and stratigraphically distinct from the Holocene, and that 
75% of the species will be extinguished in the next few 
centuries if the current tendencies continue (11). The 
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The need for digitally-enabled, integrated, person-centred care
Chairs: M Illario, I Annesi-Maesano
J Bousquet             From guidelines to digitally-enabled, integrated, person-centred care
M Erhola                 Care pathways in the Finnish national programmes
JM Anto                  Planetary health
HJ Schünemann     Next-generation guidelines
WORKING GROUPS
Group 1: Self-management
H Pinnock (chair), M Bewick, V Cardona, G Cash, M Ebisawa, D Laune, E Menditto, L Münter, J Phillips, MT Ventura
Develop a 4-page pocket guide (PG) on improved self-care (unintentional and guided) in the ICP Rhinitis, through the 
use of mobile technology with the development of an enhanced technology PG
Product: A 4-page paper and electronic document, translated in local languages using the ARIA approach
Group 2: ARIA in the pharmacy
O Lourenço, S Bosnic Anticevich (co chairs), E Costa, D Laune, E Menditto
Aim and product: Develop a 4-page pocket guide on the role of the pharmacist based on the two papers already 
finalized (ARIA in the pharmacy, Allergy and guide for pharmacists)
Group 3: Next-generation guidelines
H Schünemann (chair), I Agache, C Bachert, L Caraballo, D Chu, T Iinuma, Y Okamoto, N Pham-Thi, D Wallace
Aim: Propose a protocol and test 1-3 examples of next-generation guidelines by testing GRADE-based 
recommendations on real-life data obtained by MASK in order to confirm or refine the current recommendations.
Product: A paper on the examples and a guide for the development of the project
Group 4: Care pathways in allergen immunotherapy
J Bousquet, O Pfaar (co-chairs), I Bosse, M Calderon, GW Canonica, L Cecchi, W Czarlewski, S Durham, JL Fauquert, 
J Fonseca, L Klimek, P Kuna, V Kvedariene, D Larenas-Linneman, O Lourenço, G Marien, C Rolland, M Shamji, D 
Somekh, A Togias, I Tsiligianni, M van der Kleij, S Walker, T Zuberbier
Aim: Develop a practical guide for AIT (4 pages) including the selection of patients, patient stratification.
Product: A 4-page pocket guide
Group 5: Deployment of ICPs to other chronic respiratory diseases and sleep
G Brusselle, JL Pépin (co-chairs), I Ansotegui, JM Anto, S Bosnic Anticevich, W Fokkens, J Malva, J Mullol, U Rodts, S 
Salmi, O Usmani, S Williams
Aim: Initiate deployment to CRDs
	 Asthma and rhinitis
	 COPD
	 Chronic rhinosinusitis
Product: A short paper proposing simple steps to achieve
Group 7: Deployment of ICPs to developing countries
A Cruz (chair), N Billo, E Costa, LTT Le, M Sanchez-Borges, A Yorgancioglu
Aim: Proposal to initiate deployment to low- and middle-income countries as the GARD demonstration project (MASK).
Product: A short paper proposing simple steps to achieve and launch the COPD App to be presented at the next GARD 
meeting
Group 8: The paediatric approach
N Papadopoulos, A Valiulis
Aim: Initiate the paediatric strategy.
Product: A draft document on the strategy
Figure 1 Programme and objectives of the meeting.
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Anthropocene is characterized by an increase of the levels of 
climate warming for CO2 in the atmosphere, the ubiquitous 
presence of microplastic particles in natural waters and 
oceans, doubling levels of nitrogen and phosphorus in our 
soils, and a permanent layer of airborne particles, such as 
carbon black from the combustion of fossil fuels. These 
changes are predicted to severely disrupt our natural and 
climate systems, increase poverty and inequalities and 
severely affect our society and our planet.
So why are public health related communities reacting 
so slowly and insufficiently to the current planetary crisis? 
To answer this question, a new approach called “Planetary 
Health” has been proposed, suggesting that our current 
concept of health does not consider whether past and 
current health gains are achieved at the cost of eroding 
the Earth’s underpinning natural systems and that our 
understanding of health is insufficient (12). Planetary 
health, a new concept (4,5), is the achievement of the 
highest attainable standard of health, wellbeing, and equity 
worldwide through judicious attention to the human 
systems - political, economic and social - that shape the 
limits of Earth’s natural systems within which humanity can 
flourish.
The need for digitally-enabled, integrated, person-centred 
care
Public health policy and the importance of next-
generation pathways in non-communicable disease 
(NCD)
We are all now acutely aware of the growth of NCDs 
and of the consequential economic and health burden on 
society and individuals. The rate of growth in an ageing 
and increasingly sedentary population threatens the 
viability of health systems and ‘business as usual’ is no 
longer viable. Self-care and health literacy remain novel 
approaches to disease prevention and care pathways for 
those with established disease, despite significant evidence 
of the effectiveness of such policies. Approaches, such as 
those developed for chronic airway diseases (13,14), act as 
Figure 2 Organisations supporting the meeting: POLLAR, Impact of Air POLLution on Asthma and Rhinitis; EIT Health, European 
Institute for Innovation and Technology; EIP on AHA, European Innovation Partneship on Active and Healthy Ageing; Euforea, European 
Forum for Research and Education in Allergy and Airways Diseases; ARIA, Allergic Rhinitis and its Impact on Asthma; ACAAI, American 
College of Allergy, Asthma & Immunology, Asthma UK, Asthme and Allergies Association; CEmPac, Centre for Empowering Patients and 
Communities; EAACI, European Academy of Allergy and Clinical Immunology; EFA, European Federation of Allergy and Airways Diseases 
Patients’ Associations; EHFF, European Health Futures Forum; ERS, European Respiratory Society; GA2LEN, Global Allergy and Asthma 
European Network; GARD, Global Alliance against Chronic Respiratory Diseases (WHO Alliance); GINA, Global Initiative for Asthma; 
IPCRG, International Primary Care Respiratory Group; MACVIA, Fondation VIA-LR; SFA, Société Française d’Allergologie; SPLF, 
Societé de Pneumologie de Langue Française; WAO, World Allergy Organization; EAP, Sorbonne Université; INSERM, Institut National 
de la Santé et de la Recherche Médicale.
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examples of where effective digital interactions involving the 
patient improve clinical outcomes. Long-term supported 
interventions in the UK through the Desmond and Dafne 
schemes (15), approved by NICE, have improved care and 
control in groups under care programmes. However, there 
has been no significant impact on overall costs and resources 
as had been hoped. The public health challenge requires 
innovative approaches to health care, evidence-based around 
the patient pathway, and interventions that are successfully 
implemented by clinicians working more closely with their 
patients. The current prevalent hierarchical and pedagogic 
approach will gradually be replaced by a patient-centred one, 
where the activated health literate patient becomes an active 
participant in his/her own care and challenges professional 
and dogmatic norms. The aim is to explore how we can 
rapidly adopt already evidence-based behaviour changes in 
populations at risk of the effects of NCDs. Using examples 
from the current practice to illustrate what can be achieved, 
we will explore how public health and educational systems 
need to adapt to a rapidly changing landscape of demand.
Rhinitis and asthma: more than co-morbidity
The Asthma Phenotypes in the Inner City (APIC) 
study, conducted by the NIAID-funded Inner City 
Asthma Consortium (ICAC), was a 1-year, prospective, 
observational study in children 6–17 years of age with 
intermittent to severe persistent asthma (16-19). The study 
was designed to examine phenotypes of asthma and rhinitis 
and included standardized, longitudinal management for 
both conditions with evaluations and treatment decisions 
at every visit. Out of the 749 children and adolescents that 
were enrolled in the longitudinal evaluation/management, 
619 had at least 4 out of the 6 scheduled visits and were 
included in the phenotyping analysis.
Rhinitis was diagnosed in 93.5% of the participating 
children. Among 5 pre-specified rhinitis phenotypes, 
based on reported seasonal patterns and compatible 
allergic sensitizations at baseline, the most common and 
most severe phenotype was perennial allergic rhinitis with 
seasonal exacerbations (PARSE) (34.2%), whereas the 
least common and least severe was nonallergic rhinitis 
(NAR) (11.3%). During the prospective 1-year evaluation, 
rhinoconjunctivitis symptoms demonstrated seasonal 
oscillations compatible with the pre-determined phenotype, 
supporting the validity of history/allergic sensitization-
based classification. For all phenotypes, summertime 
represented a clear trough in symptomatology, but in no 
phenotype did symptoms disappear at any time during the 
year. Standardized rhinitis management included 3 steps: no 
treatment, oral cetirizine and nasal fluticasone propionate ± 
cetirizine. At every study visit, around 80% of the children 
with PARSE required treatment with fluticasone propionate 
± cetirizine, whereas less than 5% did not require any 
treatment. In contrast, about 50% with NAR did not require 
treatment at every visit. The remaining phenotypes ranged 
between these two extremes. In children with PARSE, 
60% among those who were receiving treatment with 
fluticasone propionate ± cetirizine remained symptomatic 
at every visit. These proportions were similar for the other 
phenotypes except for NAR, where 80% of those prescribed 
nasal corticosteroids remained symptomatic. These data 
indicate that: (I) rhinitis is almost ubiquitous in children and 
adolescents with asthma; and (II) rhinitis in children and 
adolescents with asthma is mostly moderate to severe and 
difficult to control.
The study indicated a strong relationship between 
rhinitis and asthma. At baseline, the intensity of rhinitis 
symptoms and the rhinitis medication step were among the 
strongest variables associated with whether asthma would 
be characterized as easy vs. difficult-to-control during 
the longitudinal, 1-year evaluation. In the course of the 
longitudinal evaluation, the rhinoconjunctivitis symptom 
score and the proportion of study participants requiring 
fluticasone propionate ± cetirizine were consistently 
higher in those with difficult-to-control compared to easy-
to-control asthma. In addition, causal network analysis 
identified the domain of “rhinitis severity” as having the 
strongest direct effect on the domain “asthma severity” 
independently of the domain “lung function”. A consistent 
relationship in seasonal oscillations was observed along the 
12 calendar months of the prospective evaluation among 
participants with PARSE and seasonal allergic rhinitis 
(SAR) between the rhinoconjunctivitis symptom score 
and asthma outcomes: spring peaks of rhinoconjunctivitis 
occurred at the same time as peaks in asthma outcomes 
(particularly asthma exacerbations) whereas fall peaks in 
rhinoconjunctivitis preceded peaks in asthma by 2 months.
Care pathways in the Finnish national programmes
Finland has been pioneering in implementing national 
public health programmes for respiratory diseases. Starting 
from 1994 with the asthma programme (20), the Finnish 
Lung Health Association (Filha) as the main organizer has 
continued the work with programmes for COPD 1998 
(21,22), sleep-apnoea 2002 (23), allergy 2008 (24), tuberculosis 
2013, and indoor air 2018. All programmes have shared: (I) 
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political commitment on national and regional levels; (II) 
broad consensus of opinion leaders both on specialist and 
GP levels; (III) simple and measurable goals, predefined 
activities and indicators for monitoring the result; (IV) focus 
on regional educational activities; and (V) involvement of 
multidisciplinary working groups and patient organizations 
from the outset.
In asthma, health care costs, emergency visits and 
hospitalizations have reduced markedly (20,25). Mortality is 
almost non-existent in those under the age of 60 years. The 
patients have less and milder symptoms and use medication 
more rationally. Knowledge of asthma and COPD has 
increased among professionals, as shown by an improved 
quality of asthma referral letters and lung function 
measurements with dynamic spirometry. In COPD, the 
increasing trend of hospital days has been halted by the 
programme activities. During the last 20 years, sleep apnoea 
has appeared as a significant public health problem, but is 
now treated more actively in primary health care, as guided 
by the programme.
National programmes have been a framework for 
systematic improvements in management. At patient 
level, the development of current care guidelines has given a 
solid platform for the everyday work of clinicians, nurses 
and pharmacists in health centres, specialist care and 
rehabilitation. The evidence-based guidelines have been 
produced by Duodecim, an independent and transparent 
Finnish Medical Society, working closely with medical experts. 
Currently, the guidelines are introduced to everyday 
practice by an electronic decision support system. This 
platform can also be integrated to any electronic health 
record containing structured patient data.
Finland has been active in planning and implementing 
new protocols for digital services in health care. Those 
are Virtual Hospital 2.0, led by the University Hospital 
of Helsinki. The Digital health village includes an entry 
point for patients with respiratory symptoms/diagnosis. 
Implementation and adoption of the second phase of the 
national Kanta health information services were carried 
out step-by-step from May 2010 to December 2017 
(26,27). Currently, the Kanta services include integrated, 
interoperable information from electronic medical 
and health records, personal health records, electronic 
prescribing and social welfare sources that can benefit 
patients, care providers and policy makers.
Finland has a long systematic history in the development 
of national respiratory programmes and comprehensive 
digital services that enable new openings and possibilities for 
better health support and disease management in the country.
MASK-air (The Allergy Diary)
mHealth, such as apps running on consumer smart devices, 
is becoming increasingly popular and has the potential 
to profoundly affect health care and health outcomes. 
However, it may be disruptive and results achieved are not 
always reaching the goals. Allergic Rhinitis and its Impact 
on Asthma (ARIA) has evolved from a guideline using the 
best evidence-based approach to care pathways suited to 
real-life using mobile technology in allergic rhinitis (AR) 
and asthma multimorbidity. Patients largely use over-the-
counter (OTC) medications dispensed in pharmacies. 
Shared decision making (SDM) centred around the patient 
and based on self-management should be the norm. MASK 
(Mobile Airways Sentinel NetworK), the Phase 3 ARIA 
initiative, is based on the freely available MASK app (the 
Allergy Diary, Android and iOS platforms). MASK is available 
in 17 languages and deployed in 23 countries. The potential 
usefulness of MASK will be further explored by POLLAR 
(Impact of Air POLLution on Asthma and Rhinitis), a new 
Horizon 2020 project using the Allergy Diary.
The scientific evidence of MASK-air is based on a 
validated “research” tool (The Allergy Diary up to 2018) 
that has led to large scale deployment (MASK-air, 2019–):
	 Validation of the App using COSMIN guidelines (28);
	 Baseline characteristics informed (29);
	 Work productivity associated with the control of 
allergic diseases (30,31);
	 EQ-5D is available and was found to correlate with 
baseline characteristics (32);
	 Novel phenotypes of allergic diseases were 
discovered (33);
	 Adherence to treatment is extremely low and novel 
approaches to inform the efficacy of treatment 
have been proposed (34) leading to novel studies to 
better understand guidelines (35-37).
From guidelines to digitally-enabled, integrated, 
person-centred care
MASK and POLLAR, with the help of three EU projects 
(DigitalHealthEurope, Eurifi and Vigour) recently accepted 
on the digital transformation of health, are proposing a 
second change management strategy following the ARIA 
change management (4).
In the context of implementing communication on the 
digital transformation of health and care, specifically in 
relation to chapter 5 “digital tools for citizen empowerment 
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and for person-centred care”, DG SANTE took steps to 
support the scaling-up and wider implementation of good 
practices in the field of digitally-enabled, integrated, person-
centred care. This work was carried out in collaboration 
with the newly-established Commission Expert Group 
“Steering Group on Health Promotion, Disease Prevention 
and Management of Non-Communicable Diseases”.
For this purpose, DG SANTE—in collaboration with 
the Commission’s Joint Research Centre—organized a 
“marketplace” workshop with the Joint Research Centre 
in Ispra, the third biggest European Commission site after 
Brussels and Luxembourg. The aim of this workshop was 
for representatives from Member States and other countries 
participating in the 3rd Health Programme to learn more 
about the eight good practices and key policy initiatives in 
the domain of digitally-enabled, integrated, person-centred 
care, with a view to possible transfer and replication of the 
presented practices. The ARIA digitally-enabled, integrated, 
person-centred care for rhinitis and asthma multimorbidity 
using real-world-evidence was presented. This practice is a 
GARD demonstration project.
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